TrialDiabetes, obesity & metabolism2012

Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).

Y Seino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.